The Company intends to produce products that will include the following medicinal cannabis products: transdermal patches, orally administered extracts, concentrated extracts for vaporizers and inhalers, sublingual and buccal dispensing products and possibly salves, creams, gels, lotions, and liquid extracts.

The registrant is currently working with physicians, scientists, engineers and other professionals to formulate a wide range of product delivery systems to assure our products are a precise and safe alternative as a potential treatment for chronic illness. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent disease.

Through our strategic partnership, the Company plans to launch our first series of products in 2016. In the coming months, we plan to expand our product line to include targeted treatment patches.

Transdermal Patches
Developed out of the commitment for accurate dosing and the application of pharmaceutical grade delivery methods within the cannabis industry. The registrant will develop a safe effective way to consume cannabis -- transdermally. We plan to develop up to ten different dosing formulations of patches and to continue the research to add more if the market demand is present for more variations. The patches will initially retail for approximately $10.00 per patch.
Oral Spray
Sublingual sprays provide effective, fact acting cannabinoid delivery because they are generally accepted as allowing direct access to the blood stream. Each spray of our mist will deliver 2.5 mg of cannabinoids. Every patient's metabolism is different and dosage needs vary. Each bottle shall retail for approximately $50 per bottle.